Stay up-to-date on FSR’s latest activities and learn about the ways that FSR is driving progress and accelerating research towards a cure.
FSR launched the Ignore No More: ACTe Now! Campaign (Advance Clinical Trials for Equity in Sarcoidosis) to address the underrepresentation of Black Americans in clinical trials. As part of the campaign, FSR conducted the first of its kind, IRB-approved national patient survey for Black Americans to better understand the challenges and experiences Black Americans with sarcoidosis face as it pertains to clinical trials and their disease journeys. FSR also conducted a Key Opinion Leaders Thought Workshop (KOL) and Patient Focus Group to explore the findings in greater depth and to identify recommendations for how to improve clinical trial access and overall care of Black sarcoidosis patients.
Some recommendations that emerged include building a blueprint for clinical trial design that increases access and supports diversity, clinical trial navigation and support specifically targeted for Black patients, and educational toolkits to better educate patients and physicians about trial opportunities and engagement. Though this campaign was specific to Black Americans with sarcoidosis the learnings are relevant to improving access to clinical trials for all Black Americans.
Toolkits
White Papers
Annual Updates
Press Releases
FSR Blog
Better Breather Clubs Welcome Sarcoidosis Warriors this April!
FSR is excited to once again be partnering with our friends at the American Lung Association for Sarcoidosis Awareness Month this April! This year,Learn More
Cold Weather Tips for Sarc Warriors!
We know all of our sarc warriors do not spend the winter months battling the cold weather but for those who do, it can be a big challenge!
Life as a Sarc Warrior: Making Our Medical System Work for You
Life with sarcoidosis can be hard. This is why we reached out to you, our patients, for advice on how to deal with our medical system.
Add Your Voice – Treatment Survey
FSR is partnering with pharmaceutical companies and biotechs to build a strong pipeline of potential treatments for patients with sarcoidosis and we want toLearn More
Quick links
Check out these recent updates!